Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Colitis, Ulcerative
  • Crohn Disease
  • Gastrointestinal Agents
  • Induction Chemotherapy

abstract

  • VDZ is safe and well tolerated in refractory inflammatory bowel disease patients in a clinical practice with efficacy in UC and CD with responses similar to what was seen in clinical trials.

publication date

  • August 6, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4745906

Digital Object Identifier (DOI)

  • 10.1097/MIB.0000000000000561

PubMed ID

  • 26288002

Additional Document Info

start page

  • 2879

end page

  • 85

volume

  • 21

number

  • 12